Apart from this, checkpoint inhibitor antibodies are used for activating endogenous T-cells against tumor e.g., CTLA-4, PD-1 antibodies etc. Studies have shown that polymorphism in FcYRIIa and FcYRIIIa affects the associated affinity for Fc and in turn, the efficacy of antibodies irrespective of tumor types and antigens illustrating the importance of ADCC in clinical success of these molecules [21]. Here, CTLA4 is linked to neoplasm.